<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596177</url>
  </required_header>
  <id_info>
    <org_study_id>D5670C00021</org_study_id>
    <nct_id>NCT03596177</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Exploratory study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and
      Obese Subjects with Type 2 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the
      Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes
      Mellitus
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">December 22, 2019</completion_date>
  <primary_completion_date type="Actual">December 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, Double-Blind, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in body weight, Kilograms (Kgs)</measure>
    <time_frame>Measured from Day 17 to Day 59</time_frame>
    <description>To assess the effect of MEDI0382 on body weight (Kgs) versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in total energy intake from the ad libitum lunch</measure>
    <time_frame>Measured from Day 16 to Day 32 and Day 16 to Day 59</time_frame>
    <description>To assess the effect of MEDI0382 versus placebo on energy intake during ad libitum lunchtime meals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in total energy intake from the ad libitum lunch, measured in KiloJoule (kJ)</measure>
    <time_frame>Measured from Day 16 to Day 32 and Day 16 to day 59</time_frame>
    <description>To assess the effect of MEDI0382 versus placebo on energy intake during ad libitum lunchtime meals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Total Energy Expenditure (TEE) , Active Energy Expenditure (AEE), and Resting Energy Expenditure (REE) as measured by whole room indirect calorimetry</measure>
    <time_frame>Measured from Day 15 to Day 58</time_frame>
    <description>To assess the effect of MEDI0382 versus placebo on TEE, AEE, and REE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Total Energy Expenditure (TEE), Active Energy Expenditure (AEE), and Resting Energy Expenditure (REE) as measured by whole room indirect calorimetry in kJ per kg of fat body mass</measure>
    <time_frame>Measured from Day 15 to Day 58</time_frame>
    <description>To assess the effect of MEDI0382 versus placebo on TEE, AEE, and REE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Resting Energy Expenditure (REE) as measured by hood indirect calorimetry in kJ per kg of fat body mass</measure>
    <time_frame>Measured from Day 16 to Day 32</time_frame>
    <description>To assess the effect of a 16-day period of MEDI0382 on REE. The measurements will be performed from Day 16 to Day 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Resting Energy Expenditure (REE) as measured by hood indirect calorimetry in kJ per kg of fat body mass</measure>
    <time_frame>Measured from Day 16 to Day 32</time_frame>
    <description>To assess the effect of a 16-day period of MEDI0382 on REE. The measurements will be performed from Day 16 to Day 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in total energy expenditure as measured by doubly labelled water from baseline (Day 17) to the end of treatment (Day 58 or 59)</measure>
    <time_frame>Measured from Day 17 to Day 58 or Day 59 (as is a flexible visit)</time_frame>
    <description>To assess the effect of MEDI0382 versus placebo on TEE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in total energy expenditure as measured by doubly labelled water in kJ per kg of fat body mass from baseline (Day 17) to the end of treatment (Day 58 or 59)</measure>
    <time_frame>Measured from Day 17 to Day 58 or Day 59 (as is a flexible visit)</time_frame>
    <description>To assess the effect of MEDI0382 versus placebo on TEE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight in kg on measures of body weight and composition versus placebo</measure>
    <time_frame>Measured from Day 17 to Day 59</time_frame>
    <description>To assess the effect of MEDI0382 on change in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight in kg on measures of body weight and composition versus placebo using Dual energy X-ray (DXA)</measure>
    <time_frame>Measured from Day -1 to Day 59</time_frame>
    <description>To assess change in absolute change in total body fat mass as measured by DXA in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in body weight on measures of body weight and composition versus placebo using DXA</measure>
    <time_frame>Measured from Day -1 to Day 59</time_frame>
    <description>To assess change in percentage change in total body fat mass as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight in kgs on measures of body weight and composition versus placebo using DXA</measure>
    <time_frame>Measured from from Day -1 to 59</time_frame>
    <description>To assess change in absolute change in total body fat mass: lean mass ratio as measured by DXA in Kgs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in body weight on measures of body weight and composition versus placebo using DXA</measure>
    <time_frame>Measured from from Day -1 to 59</time_frame>
    <description>To assess change percentage change in total body fat mass: lean mass ratio as measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose during a Mixed Meal Tolerance test (MMTT)</measure>
    <time_frame>Measured from Day -1 to Day 59</time_frame>
    <description>To assess the effect of MEDI0382 on glucose homeostasis versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in glucose under the plasma concentration time curve (AUC) during a MMTT</measure>
    <time_frame>Measured from Day -1 to 59</time_frame>
    <description>To assess the effect of MEDI0382 on glucose homeostasis versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Immunogenicity and titre (if confirmed Immunogenicity-positive)</measure>
    <time_frame>Measured on Day 17, Day 32, Day 59 and Day 87 (follow-up)</time_frame>
    <description>Characterising the immunogenicity profile of MEDI0382 exposure versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of MEDI0382 versus placebo, by measuring change in systolic blood pressure</measure>
    <time_frame>Measured from baseline(Day -1) to Day 87 (follow up)</time_frame>
    <description>Assess safety by change in systolic blood pressure from baseline (Day -1) to Day 87 (follow up)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of MEDI0382 versus placebo, by measuring change diastolic blood pressure</measure>
    <time_frame>Measured from baseline(Day -1) to Day 87 (follow-up)</time_frame>
    <description>Assess safety by change in diastolic blood pressure from baseline (Day -1) to Day 87 (follow up)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of MEDI0382 versus placebo, by measuring change in pulse rate</measure>
    <time_frame>Measured from baseline(Day -1) to Day 87 (follow-up)</time_frame>
    <description>Assess safety by change in pulse rate from baseline (Day -1) to Day 87 (follow up)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of MEDI0382 versus placebo, by measuring change in temperature</measure>
    <time_frame>Measured from baseline(Day -1) to Day 87 (follow-up)</time_frame>
    <description>Assess safety by change in temperature from baseline (Day -1) to Day 87 (follow up)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of MEDI0382 versus placebo, by using Electrocardiography (ECG)</measure>
    <time_frame>Measured on Day 17, Day 59 and Day 87 (follow-up)</time_frame>
    <description>The safety of the subjects will be measured by performing ECG assessments to check for any clinically significant findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of MEDI0382 versus placebo by collecting blood samples for Safety laboratory analysis</measure>
    <time_frame>Measured from baseline(Day -1) to Day 87 (follow-up)</time_frame>
    <description>The Safety of the subjects will be evaluated by collecting blood samples for Safety laboratory analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of safety and tolerability of MEDI0382 as assessed by Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE V4.0</measure>
    <time_frame>Up to Day 87 (follow-up)</time_frame>
    <description>The safety of the subjects in the study will be evaluated by recording all Trial Emergent Adverse Events (TEAEs) As assessed by CTCAE V4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of safety and tolerability of MEDI0382 as assessed by Treatment Emergent Serious Adverse Events (TESAEs) as assessed by CTCAE V4.0</measure>
    <time_frame>Up to Day 87 (follow-up)</time_frame>
    <description>The safety of the subjects in the study will be evaluated by recording all Trial Emergent Serious Adverse Events(TESAEs) as assessed by CTCAE V4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of safety and tolerability of MEDI0382 as assessed by Adverse Events of Special Interest (AESIs) as assessed by CTCAE V4.0</measure>
    <time_frame>Up to Day 87 (follow-up)</time_frame>
    <description>The safety of the subjects in the study will be evaluated by recording all Adverse Events of Special Interest (AESIs) as assessed by CTCAE V4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>MEDI0382</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0382 administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI0382</intervention_name>
    <description>MEDI0382 administered subcutaneously</description>
    <arm_group_label>MEDI0382</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged ≥ 30 and ≤ 75 years at screening

          2. Provision of signed and dated written informed consent (except for consent for genetic
             and non-genetic research and additional optional assessments) prior to any
             protocol-related procedures

          3. Body Mass Index &gt; 28 and ≤ 40 kg/m^2 at screening

          4. Glycated haemoglobin (HbA1c) ≤ 8.0% at screening

          5. Diagnosed with Type 2 Diabetes (T2DM) with glucose control managed with metformin,
             with or without a DPPIV inhibitor, Sodium-glucose co-transporter-2 inhibitors
             (SGLT2i), sulfonylurea, or meglitinide, where no significant dose change (increase or
             decrease &gt; 50%) has occurred in the 3 months prior to screening; if the subject is on
             dual therapy, a 4-week washout of the non-metformin therapy (DPPIV inhibitor, SGLT2i,
             sulfonylurea, or meglitinide) will be required prior to Visit 4.

          6. Female subjects of childbearing potential must have a negative pregnancy test at
             screening and randomisation, and must not be lactating.

          7. Female subjects of childbearing potential who are sexually active with a
             non-sterilised male partner must be using at least one highly effective method of
             contraception (see Section 10.2 for definition of females of childbearing potential
             and for a description of highly effective methods of contraception) from screening and
             must agree to continue using such precautions up until 4 weeks after the last dose of
             investigational product

        Exclusion Criteria:

          1. History of, or any existing condition(s) that, in the opinion of the investigator,
             would interfere with evaluation of the investigational product, put the subject at
             risk, influence the subject's ability to participate or affect the interpretation of
             the results of the study and/or any subject unable or unwilling to follow study
             procedures

          2. Any subject with a cardiac pacemaker or implanted/portable electronic device

          3. Any subject who has received another investigational product as part of a clinical
             study or a Glucagon-like peptide-1 (GLP-1) analogue-containing preparation within the
             last 30 days or 5 half-lives of the drug (whichever is longer) at the time of
             screening (Visit 1)

          4. Any subject who has received any of the following medications within the specified
             timeframe prior to Visit 2: herbal preparations or drugs licensed for control of body
             weight or appetite (eg, orlistat, bupropion, naltrexone, phentermine-topiramate,
             phentermine, lorcaserin, opiates, domperidone, metoclopramide, or other drugs known to
             alter gastric emptying)

          5. Concurrent participation in another study with an investigational product and prior
             randomisation in this study is prohibited

          6. Severe allergy/hypersensitivity to any of the proposed study treatments, excipients,
             or standardised meals

          7. Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight
             loss), a history of type 1 diabetes mellitus or diabetic ketoacidosis, or if the
             subject has been treated with daily Subcutaneous (SC) insulin within 90 days prior to
             screening.

          8. Abnormal thyroid stimulating hormone (TSH) level of &lt; 0.03 Milli-International Units
             Per Litre (mIU/L) or &gt; 10 Milli-International Units Per Litre (mIU/L) confirmed on two
             consecutive tests

          9. Regularly engage in high intensity exercise at least three times per week or have done
             so in the prior three months

         10. Clinically significant inflammatory bowel disease, gastroparesis or other severe
             disease or surgery affecting the upper GI tract (including weight-reducing surgery and
             procedures) which may affect gastric emptying or could affect the interpretation of
             safety and tolerability data

         11. Acute or chronic pancreatitis

         12. Significant hepatic disease (except for nonalcoholic steatohepatitis or nonalcoholic
             fatty liver disease without portal hypertension or cirrhosis) and/or subjects with any
             of the following results at screening:

               1. Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)

               2. Alanine transaminase (ALT) ≥ 3 × ULN

               3. Total bilirubin ≥ 2 × ULN

         13. Impaired renal function defined as estimated glomerular filtration rate (eGFR) &lt; 45
             mL/minute/1.73 m2 at screening (GFR estimated according to the Chronic Kidney
             Disease-Epidemiology Collaboration (CKD-EPI) or the Modification of Diet in Renal
             Disease (MDRD) using MDRD Study Equation isotope dilution mass spectrometry-traceable
             [International System of Units (SI) units]

         14. Poorly controlled hypertension defined as:

               1. Systolic BP &gt; 180 mm Hg

               2. Diastolic BP or &gt; 100 mm Hg After 10 minutes of supine rest and confirmed by
                  repeated measurement at screening.

             Subjects who fail BP screening criteria may be considered for 24-hour ambulatory blood
             pressure monitoring at the discretion of the investigator. Subjects who maintain a
             mean 24-hour BP ≤ 180/100 mmHg with a preserved nocturnal dip of &gt; 15% will be
             considered eligible

         15. Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke
             within 3 months prior to screening, or subjects who have undergone percutaneous
             coronary intervention or a coronary artery bypass graft within the past 6 months or
             who are due to undergo these procedures at the time of screening

         16. Severe congestive heart failure (New York Heart Association Class III or IV)

         17. Basal calcitonin level &gt; 50 ng/L at screening or history/family history of medullary
             thyroid carcinoma or multiple endocrine neoplasia

         18. History of neoplastic disease within 5years prior to screening, except for adequately
             treated basal cell, squamous cell skin cancer, or in situ cervical cancer

         19. Any positive results for serum hepatitis B surface antigen (HBsAg), hepatitis C
             antibody and human immunodeficiency virus (HIV) antibody

         20. Substance dependence or history of alcohol abuse and/or excess alcohol intake

         21. Involvement of any AstraZeneca, Medimmune Ltd, contract research organization (CRO),
             or National Institute for Health Research/Wellcome Trust Cambridge Clinical Research
             Facility employee or their close relatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type II</keyword>
  <keyword>Obesity</keyword>
  <keyword>MEDI0382</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

